Nephrotrans (Sodium Hydrogen Carbonate)

Sodium Hydrogen Carbonate, the active ingredient in Nephrotrans, is a chemical compound presented as an oral preparation for oral use. It helps neutralize excess acid in the stomach, urine or systemic circulation, thereby supporting acid‑base balance in patients who need alkalinisation. GNH USA supplies Nephrotrans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nephrotrans, containing sodium hydrogen carbonate, is used to manage conditions related to excess acidity in the body.

- Metabolic acidosis: helps correct systemic acid‑base imbalance by providing bicarbonate ions. - Gastric hyperacidity: reduces stomach acidity and relieves heartburn or indigestion. - Urinary alkalinization: raises urine pH to facilitate excretion of certain drugs and prevent stone formation.

Sodium hydrogen carbonate is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset after ingestion. - Belching: release of gas due to increased gastric alkalinity. - Abdominal discomfort: occasional cramping or fullness. - Flatulence: excess gas production in the intestines.

Serious or Rare Side Effects: - Metabolic alkalosis: excessive rise in blood pH. - Hypokalemia: low potassium levels, especially with prolonged use. - Hypernatremia: elevated sodium concentration in the blood. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before using Nephrotrans, consider the following safety measures.

- Assess renal function: impaired kidneys may reduce bicarbonate excretion. - Monitor electrolytes: watch for changes in potassium and sodium levels. - Avoid in severe hypertension: excess sodium can increase blood pressure. - Use caution in pregnancy: limited data, so evaluate risk‑benefit. - Store at ambient temperature: keep in the original pack, protect from moisture.

Sodium hydrogen carbonate can affect the action of other medicines.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia when combined. - Certain antibiotics (e.g., quinolones): reduced absorption and effectiveness.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood‑pressure‑lowering effect. - Corticosteroids: increased sodium load can affect fluid balance. - Other alkalinizing agents: potential for metabolic alkalosis when used together.